Drug Approval | March 22, 2023
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Rocuronium Bromide Injection had an annual sale of approximately US $53 million in the US (IQVIA MAT December 2022)
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The observations are procedural in nature
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
Biocorp will receive an initial milestone payment this year
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
The inspection concluded with no observations
Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body
Subscribe To Our Newsletter & Stay Updated
